Integra LifeSciences Holdings (IART)
Working capital turnover
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (ttm) | US$ in thousands | 1,596,615 | 1,533,335 | 1,521,985 | 1,473,066 | 1,486,381 | 1,488,778 | 1,493,656 | 1,509,844 | 1,505,291 | 1,519,581 | 1,519,648 | 1,510,233 | 1,535,982 | 1,529,270 | 1,504,267 | 1,371,086 | 1,317,264 | 1,323,744 | 1,339,441 | 1,466,719 |
| Total current assets | US$ in thousands | 1,081,680 | 1,099,520 | 1,112,290 | 1,415,650 | 1,058,040 | 1,027,230 | 1,051,260 | 1,029,480 | 1,161,500 | 1,196,450 | 1,137,410 | 1,066,050 | 1,153,720 | 1,103,780 | 1,032,380 | 1,039,080 | 1,237,200 | 1,152,100 | 966,222 | 1,008,670 |
| Total current liabilities | US$ in thousands | 922,126 | 912,563 | 328,316 | 302,394 | 306,980 | 355,712 | 377,496 | 282,293 | 320,906 | 304,452 | 295,596 | 315,833 | 340,021 | 332,858 | 318,756 | 412,301 | 401,013 | 255,146 | 212,415 | 246,485 |
| Working capital turnover | 10.01 | 8.20 | 1.94 | 1.32 | 1.98 | 2.22 | 2.22 | 2.02 | 1.79 | 1.70 | 1.81 | 2.01 | 1.89 | 1.98 | 2.11 | 2.19 | 1.58 | 1.48 | 1.78 | 1.92 |
December 31, 2024 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $1,596,615K ÷ ($1,081,680K – $922,126K)
= 10.01
Integra LifeSciences Holdings' working capital turnover ratio has shown fluctuations over the periods analyzed. The ratio measures how efficiently the company is managing its working capital to generate sales revenue.
The trend indicates that the working capital turnover ratio generally increased from March 31, 2020, to June 30, 2021, showing improved efficiency in utilizing its working capital. However, there was a decline in the ratio from September 30, 2021, to December 31, 2021, which suggests a temporary decrease in efficiency in this period.
Notably, the ratio significantly increased in the following periods up to September 30, 2024, reaching a very high value of 10.01, indicating that the company was able to generate a high level of sales revenue relative to its working capital during this period.
The spike in the working capital turnover ratio in the latter part of 2024 may signal either enhanced efficiency in working capital management or a substantial increase in sales revenue. Further analysis is needed to understand the reasons behind this significant spike and whether it is sustainable in the long term.
Peer comparison
Dec 31, 2024